国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial

第一作者：Mengyuan Zhou,Weiqi Chen

通讯作者：Yilong Wang

antiplatelet clopidogrel high platelet reactivity inhibition of platelet aggregation ticagrelor

基本信息

2020-12-19

已发表文章

发表杂志：Aging

发表类型: Original Contributions

影响因子(IF): 4.831

PMID: 33411687 Pubmed原文链接 全文下载

主要研究背景及目的

Studies on antiplatelet effect of ticagrelor/aspirin and clopidogrel/aspirin in patients with acute minor strokeand transient ischemic attack (TIA) stratified by CYP2C19 metabolizer status is limited.

方法

We gained data from thePlatelet Reactivity In Non-disabling Cerebrovascular Events study. Platelet reactivity was tested at baseline, 2 hours, 24 hours, 7 days and 90 days after initial dose, including high on-treatment platelet reactivity (HOPR), which was defined as P2Y12 reaction unit >208, and percentage inhibition of platelet aggregation (IPA).

结论

Our findings showed that ticagrelor/aspirin therapy possessed greater platelet inhibition and more rapid onset in platelet inhibition compared with clopidogrel/aspirin therapy both in carriers and non-carriers of CYP2C19 lose-of-function alleles with acute minor stroke or TIA.

主要结果

A total of 365 patients were included. There were 199 (54.5%) individuals lassified as carriers of CYP2C19 loss-offunction alleles. For carriers and non-carriers, the proportions of HOPR were significantly lower in those with ticagrelor/aspirin compared with those with clopidogrel/aspirin at 2 hours, 24 hours, 7 days, respectively (all p<0.05). IPA was higher at all time points except at baseline in patients with ticagrelor/aspirin compared with those with clopidogrel/aspirin in both carriers and non-carriers of CYP2C19 lose-of-function alleles (all p<0.05).